ERBB2 and neoplasm: They found that all non-compliant decisions concerned mostly a group of patients and decisions (i.e. elderly patients in pre-surgery decisions, patients with micro-invasive tumour in re-excision decisions, and patients with positive hormone receptors and HER2+ in adjuvant decisions).